← Leaderboards
Iwao Ojima
State University New York Stony Brook
$7,814,090
Attributed
$10,886,683
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $782.2K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,886,683 · 7
By mechanism
R01$10,510,488 · 6
R21$376,195 · 1
Top collaborators
- Robert C. Rizzo6 shared
- Martin Kaczocha5 shared
- Lloyd C Trotman5 shared
- Michael Virgil Airola1 shared
- Maurizio Del Poeta1 shared
Most similar at State University New York Stony Brook
Same institution · by research overlap
- Scott McNeill Sieburth$1,797,607
- Galina I Botchkina$370,501
- Robert C. Rizzo$7,144,550
- Michael Virgil Airola$3,835,845
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignIn VitroIn VivoGenerationsCellsLeadTaxaneResistanceReceptorDrug DiscoveryPharmaceutical PreparationsCytotoxicityAntineoplastic AgentsChemical SynthesisMolecularProteinsPublic Health RelevanceToxic EffectAnimal ModelCytochrome P450MicrotubulesBaseAntibioticsPrograms
Grant awards (29)
Developing new antifungals against sterolglycosidases$782,178
R01 · FY2025 · AI
Development of the Next Generation of FABP5 Inhibitors to Treat Prostate Cancer$629,362
R01 · FY2024 · CA · contact PI
Development of the Next Generation of FABP5 Inhibitors to Treat Prostate Cancer$654,000
R01 · FY2023 · CA · contact PI
Development of the Next Generation of FABP5 Inhibitors to Treat Prostate Cancer$658,627
R01 · FY2022 · CA · contact PI
Development of the Next Generation of FABP5 Inhibitors to Treat Prostate Cancer$676,650
R01 · FY2021 · CA · contact PI
Development of the Next Generation of FABP5 Inhibitors to Treat Prostate Cancer$695,974
R01 · FY2020 · CA · contact PI
Novel Antimicrobials Targeting Cell Division$353,254
R01 · FY2013 · AI · contact PI
Tumor -Targeting Chemotherapeutic Agents$295,691
R01 · FY2013 · CA · contact PI
Novel Antimicrobials Targeting Cell Division$376,023
R01 · FY2012 · AI · contact PI
Tumor -Targeting Chemotherapeutic Agents$314,565
R01 · FY2012 · CA · contact PI
Novel Antimicrobials Targeting Cell Division$376,282
R01 · FY2011 · AI · contact PI
Tumor -Targeting Chemotherapeutic Agents$314,565
R01 · FY2011 · CA · contact PI
Novel Antimicrobials Targeting Cell Division$379,116
R01 · FY2010 · AI · contact PI
Tumor -Targeting Chemotherapeutic Agents$323,606
R01 · FY2010 · CA · contact PI
Novel Antimicrobials Targeting Cell Division$385,945
R01 · FY2009 · AI · contact PI
Tumor -Targeting Chemotherapeutic Agents$322,229
R01 · FY2009 · CA · contact PI
Taxane and Taxoid Chemotherapeutic Agents$301,814
R01 · FY2007 · CA · contact PI
Taxane and Taxoid Chemotherapeutic Agents$308,375
R01 · FY2006 · CA · contact PI
Taxane and Taxoid Chemotherapeutic Agents$315,459
R01 · FY2005 · CA
Taxane and Taxoid Chemotherapeutic Agents$315,796
R01 · FY2004 · CA
Drug Discovery &Biodiversity Conservation in Madagascar$198,195
R21 · FY2004 · TW
Taxane and Taxoid Chemotherapeutic Agents$337,061
R01 · FY2003 · CA
NEW SYNTHESIS OF BIOCHEMICALS WITH HOMOGENEOUS CATALYSTS$259,667
R01 · FY2003 · GM
Drug Discovery &Biodiversity Conservation in Madagascar$178,000
R21 · FY2003 · TW
NEW SYNTHESIS OF BIOCHEMICALS WITH HOMOGENEOUS CATALYSTS$259,561
R01 · FY2002 · GM
NON-PROTEIN AMINO ACIDS AND TAXOID ANTITUMOR AGENTS$92,046
R01 · FY2002 · GM
NON-PROTEIN AMINO ACIDS AND TAXOID ANTITUMOR AGENTS$268,555
R01 · FY2001 · GM
NEW SYNTHESIS OF BIOCHEMICALS WITH HOMOGENEOUS CATALYSTS$252,770
R01 · FY2001 · GM
NON-PROTEIN AMINO ACIDS AND TAXOID ANTITUMOR AGENTS$261,317
R01 · FY2000 · GM